Clinical outcome in 1000 patients with localized prostate cancer treated with external beam radiotherapy and high-dose-rate 192-Iridium brachytherapy boost: A single institution experience

Brachytherapy ◽  
2008 ◽  
Vol 7 (2) ◽  
pp. 93-94
Author(s):  
Enrique Castellanos ◽  
Gabriella Cohn-Cedermark ◽  
Anders Ullen ◽  
Katinka Sandberg ◽  
Marianne Ryberg ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Outcome ◽  
Dose Rate ◽  
External Beam Radiotherapy ◽  
High Dose Rate ◽  
Localized Prostate Cancer ◽  
High Dose ◽  
External Beam ◽  
Single Institution ◽  
Brachytherapy Boost

scholarly journals Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: A 6-year follow-up

2007 ◽  
Vol 46 (7) ◽  
pp. 909-917 ◽  
Author(s):  
Karl Mikael Kälkner ◽  
Thomas Wahlgren ◽  
Marianne Ryberg ◽  
Gabriella Cohn-Cedermark ◽  
Enrique Castellanos ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Outcome ◽  
Dose Rate ◽  
External Beam Radiotherapy ◽  
High Dose Rate ◽  
High Dose ◽  
External Beam ◽  
Brachytherapy Boost ◽  
Iridium 192

scholarly journals Two-Weekly High-Dose-Rate Brachytherapy Boost After External Beam Radiotherapy for Localized Prostate Cancer: Long-Term Outcome and Toxicity Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Jörg Tamihardja ◽  
Paul Lutyj ◽  
Johannes Kraft ◽  
Dominik Lisowski ◽  
Stefan Weick ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Dose Rate ◽  
External Beam Radiotherapy ◽  
High Dose Rate ◽  
Localized Prostate Cancer ◽  
High Dose ◽  
High Dose Rate Brachytherapy ◽  
Brachytherapy Boost ◽  
Gi Toxicity

PurposeEvaluation of clinical outcome of two-weekly high-dose-rate brachytherapy boost after external beam radiotherapy (EBRT) for localized prostate cancer.Methods338 patients with localized prostate cancer receiving definitive EBRT followed by a two-weekly high-dose-rate brachytherapy boost (HDR-BT boost) in the period of 2002 to 2019 were analyzed. EBRT, delivered in 46 Gy (DMean) in conventional fractionation, was followed by two fractions HDR-BT boost with 9 Gy (D90%) two and four weeks after EBRT. Androgen deprivation therapy (ADT) was added in 176 (52.1%) patients. Genitourinary (GU)/gastrointestinal (GI) toxicity was evaluated utilizing the Common Toxicity Criteria for Adverse Events (version 5.0) and biochemical failure was defined according to the Phoenix definition.ResultsMedian follow-up was 101.8 months. 15 (4.4%)/115 (34.0%)/208 (61.5%) patients had low-/intermediate-/high-risk cancer according to the D`Amico risk classification. Estimated 5-year and 10-year biochemical relapse-free survival (bRFS) was 84.7% and 75.9% for all patients. The estimated 5-year bRFS was 93.3%, 93.4% and 79.5% for low-, intermediate- and high-risk disease, respectively. The estimated 10-year freedom from distant metastasis (FFM) and overall survival (OS) rates were 86.5% and 70.0%. Cumulative 5-year late GU toxicity and late GI toxicity grade ≥ 2 was observed in 19.3% and 5.0% of the patients, respectively. Cumulative 5-year late grade 3 GU/GI toxicity occurred in 3.6%/0.3%.ConclusionsTwo-weekly HDR-BT boost after EBRT for localized prostate cancer showed an excellent toxicity profile with low GU/GI toxicity rates and effective long-term biochemical control.

Sign in / Sign up

Export Citation Format

Share Document